Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

Completed · Phase 1

Conditions studied: Renal Impairment

In brief

This study will be assessing the pharmacokinetics of NKTR-118 in subjects with renal impairment compared to that in subjects with normal renal function.

Key facts

Study ID

NCT01372826

Run by

AstraZeneca

People needed

32

Starts

2011-06-01

Expected to finish

2011-11-01

Last updated by the study team

2014-10-15

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Provision of signed written and dated informed consent prior to any study specific procedures.
• Male or female volunteers aged 18 to 80 years (inclusive) having normal renal function, or suffering from moderate or severe renal impairment or ESRD.
• Male subjects who are sexually active must be willing to use a barrier method of contraception (condom). Women must be of non-childbearing potential or, if of childbearing potential, must have a negative pregnancy test (at screening and at each admission) and be using a highly effective form of birth control for 3 months before enrollment and be willing to use a highly effective form of birth control during the study and until 3 months after their last dose of IP.
• Have a BMI between 18 and 40 kg/m2 (inclusive) and weigh at least 50 kg.
• Subjects must be able to understand and to comply with study procedures, restrictions and requirements.

You may not qualify if…

• History of any clinically significant medical history which, in the opinion of the Investigator and Sponsor, may either put the subject at risk because of participation in the study, or influence the results, or the subject's ability to participate in the study.
• History or presence of gastrointestinal hepatic or other condition known to interfere with disposition of the study drug (except for renal function impairment).
• Subjects who have a functioning kidney transplant.
• Acute illness, surgical procedures or trauma from within 2 weeks before enrollment until first administration of study drug
• Known or suspected history of drug abuse as judged by the Investigator.

Where it is running

• Research Site — Anaheim, California, United States
• Research Site — Orlando, Florida, United States
• Research Site — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.